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Summary We report below an in vivo antimalarial efﬁcacy study conducted in 2002 in Bundi Bugyo, a district of
western Uganda housing a large displaced population. We tested sulfadoxine–pyrimethamine (SP),
amodiaquine (AQ) and the combination chloroquine plus SP (CQ + SP). A total of 268 children with
uncomplicated Plasmodium falciparum malaria were followed-up for 28 days according to WHO
recommendations, with PCR genotyping to distinguish late recrudescences from re-infections.
PCR-adjusted failure proportions at day 28 were 37.0% (34/92, 95% CI 27.1–47.7) in the SP group,
20.6% (14/68, 95% CI 11.7–32.1) in the AQ group and 22.8% (18/79, 95% CI 14.1–33.6) in the
CQ + SP group. Early failures were particularly frequent in the SP group (15.2%). Clearance of
gametocytes was slower in the SP and CQ + SP groups than in the AQ group. This study suggests that, in
Bundi Bugyo, CQ + SP (Uganda’s ﬁrst-line regimen) will need to be replaced by a more efﬁcacious
regimen. Across Uganda, the deployment of SP containing combinations may not be a feasible long-term
strategy. For Bundi Bugyo, we recommend a combination of artesunate and AQ. Our study also
conﬁrms previous ﬁndings that resistance is considerably underestimated by 14-day follow-ups.
Antimalarial policy decisions should therefore be based on 28-day studies, with PCR adjustment to
distinguish re-infections.
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Introduction
Throughout Africa, increasing Plasmodium falciparum
resistance to common antimalarials poses a formidable
obstacle for malaria control. Uganda, which in 2001
declared 5 622 934 cases of malaria (39% of all outpatient
consultations), is particularly affected by this problem
(Ministry of Health of Uganda 2003). Therapeutic failure
to chloroquine (CQ) reaches 76% in Kampala (Kamya
et al. 2001), 81% in Mbarara (Legros et al. 2002) and 10–
48% in other sentinel sites of the East African Network for
Monitoring Antimalarial Treatment (EANMAT) (Kamya
et al. 2002). Resistance to sulfadoxine–pyrimethamine (SP)
is also increasing, with 18% failure in Kampala (Dorsey
et al. 2002), 25% in Mbarara (Legros et al. 2002) and
6–19% in other EANMAT sites (Kamya et al. 2002). The
above data are based on 14-day patient follow-ups, and
clinical classiﬁcation criteria (EANMAT 1999).
Bundi Bugyo District of western Uganda, bordering the
Democratic Republic of the Congo, houses a large
population displaced from mountain villages due to
armed conﬂict. Since 1997, the medical relief organization
Me ´decins Sans Frontie `res (MSF) has been supporting the
district’s health facilities. Malaria, diagnosed mostly on
clinical grounds, seemed a dominant problem in Bundi
Bugyo hospital, accounting from November 2000 to June
2001 for 33% of consultations, 49% of admissions and
50% of inpatient deaths (MSF, unpublished data). Little
was known, however, about the efﬁcacy of antimalarials
in this region, apart from a 1997 study showing 33% and
5% clinical failure of CQ and SP, respectively (Kilian
AHD, Prislin I, Kabagambe G et al., 1997, unpublished
report).
In an effort to explore possible alternatives to CQ, we
decided in 2001 to conduct an in vivo study of SP and
amodiaquine (AQ) among children less than 5 years of age
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Uganda introduced a new national recommendation for
treatment of uncomplicated malaria, consisting of a com-
bination of CQ and SP (CQ + SP) as ﬁrst-line treatment.
This provisional policy assumed that such a combination
would provide better efﬁcacy than CQ or SP alone, and
protect partner drugs against further development of
resistance; it equally reﬂected insufﬁcient evidence on other
potential alternatives (Kamya et al. 2002). CQ + SP,
however, had not yet been studied in Uganda, and in Africa
only one trial was reported (Bojang et al. 1998). In order to
gain more information about the efﬁcacy of this new
protocol, we added a third, CQ + SP, group to our study.
Methods
Study site and population
The plains of Bundi Bugyo district (altitude 700–900 m)
experience perennial malaria transmission, with peaks in
July and December. Plasmodium falciparum is the pre-
dominant species reported (98%), with Anopheles gambiae
and Anopheles funestus as the main vectors (Jelinek et al.
1996). At the time of writing, about 137 000 displaced
persons were settled in 63 makeshift camps scattered across
this area. An evaluation of a mass distribution of bednets in
2001showed76%coverageanda9%communityprevalence
of P. falciparum infection (Spencer S., Grant A. D., Piola P.
etal.,submitted).Werecruitedchildrenwithuncomplicated
P. falciparum malaria from the outpatient departments of
Bundi Bugyo District Hospital, and the nearby Nyahuka
Health Centre. A study clinic was established within Bundi
Bugyo hospital. The study was approved and supported by
the Ugandan Ministry of Health.
Inclusion criteria and procedures
The study was based on current WHO and EANMAT
recommendations (EANMAT 1999; WHO 2002).
Accordingly, children aged 6–59 months with fever (axil-
lary temperature ‡37.5  C) or history of fever in the past
24 h were screened from outpatient lines. In Nyahuka, a
preliminary Paracheck
 rapid test was also performed so as
to minimize unnecessary transport to the study clinic.
Children with a P. falciparum mono-infection and asexual
parasitaemia 1000–100 000 ll
)1 were eligible for the
study. Exclusion criteria were (i) signs of severity or severe
malaria (WHO 2000a), (ii) reported intake of a full course
of antimalarials in the previous 7 days, (iii) history of
allergic reactions to the study drug and (iv) presence of a
concomitant febrile condition with the potential to
confound study outcome (e.g. ARI, measles, severe diar-
rhoea, severe wounds, etc.; mild inﬂuenza cases were not
excluded). Written, informed consent was obtained by
signature or ﬁngerprint from parents or guardians.
Treatment and follow-up
Study regimens consisted of SP 1.25 mg/kg stat
(Falcidin
 ,Cosmos Ltd., Nairobi), AQ 30 mg/kg base
divided into three daily doses of 10 mg/kg (Malaratab
 ,
Cosmos Ltd., Nairobi) and CQ 25 mg/kg base given at
10 mg/kg on day 0 and day 1, and 5 mg/kg on day 2 (Ipca
Laboratories Ltd., Mumbai), plus an SP stat dose as above.
Study drugs came from approved EANMAT sources. All
doses were directly observed and repeated after 30 min in
case of vomiting or spitting. On day 0, haemoglobin and
gametocyte carriage were also recorded, and a blood
sample collected for possible genotypic analysis to distin-
guish recrudescences from re-infections.
After treatment (days 0, 1 and 2), children were
re-assessed clinically and parasitologically on days 3, 7, 14,
21 and 28. If children were parasitaemic but asymptomatic
during follow-up, additional home visits were performed
so as to prevent aggravation (according to WHO and
EANMAT guidelines, treatment is withheld for such
children until either appearance of symptoms or day 28).
Haemoglobin and gametocytaemia were re-measured on
days 14 and 28, and a second blood sample collected in
case parasites reappeared after day 9. Rescue therapy
(quinine hydrochloride 10 mg/kg/8 h for 7 days) was
administered upon treatment failure (see below).
The three regimens were tested sequentially (SP, then
AQ, then CQ + SP). We decided against a randomized
design mainly because of poor security in the area, leading
to a strong risk of early study interruption, and thus failure
to reach a sufﬁcient sample size in any arm.
Outcome classiﬁcation
Children were withdrawn from the study in case of (i)
vomiting any study dose twice, (ii) serious allergic reaction
to the study drug, (iii) onset of a serious febrile illness or
(iv) intake of any drug with antimalarial properties.
Children who skipped any dose or scheduled visit despite
tracing were considered lost to follow-up. Remaining
outcomes were classiﬁed according to WHO 2001 criteria:
early treatment failure (ETF) in case of (i) progression to
severe malaria by day 3, (ii) parasitaemia on day 2 > day 0,
(iii) parasitaemia on day 3 ‡ 25% of day 0 or (iv) fever and
parasitaemia on day 3; late clinical failure (LCF) any time
from day 4 to day 28 in case of (i) progression to severe
malaria or (ii) fever plus parasitaemia; and late parasito-
logical failure (LPF) in case of afebrile parasitaemia
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an adequate clinical and parasitological response (ACPR).
Laboratory methods
Capillary blood was obtained by ﬁnger prick. Thick and
thin ﬁlms, prepared on the same slide, were stained with
10% Giemsa (pH 7.2) for 12 min. Asexual parasitaemia
was quantiﬁed against 200–500 leukocytes, assuming a
normal level of 8000 leukocytes/ll (WHO 1991). Presence
of gametocytes was noted. All study slides were re-read
blindly by a second microscopist, and any discordances
resolved by a third, experienced reader. External controls
were conducted by a Ministry of Health expert, and at the
Mbarara University of Science and Technology, where, on
a sample of 97 slides, concordance was 91%. Haemoglo-
bin was measured using the Lovibond technique (Assistant
Co., Sondheim Rhon, Germany). Axillary temperature
readings were taken using a digital thermometer, and were
monitored during the ﬁrst month of the study.
Blood samples for PCR genotypic analysis were collected
on Isocode
  kits (Schleicher & Schuell, Ecquevilly, France).
Only failures after day 9 were analysed by PCR. The
analysis was performed by the Shoklo Malaria Research
Unit, Mae Sot, Thailand, according to a published method
considering the three P. falciparum gene loci merozoite
surface protein-1 (msp-1), merozoite surface protein-2
(msp-2) and glutamate rich protein (GLURP) (Brockman
et al. 1999). Brieﬂy, this method allows for comparison of
the genotype of pre- (inclusion) and post-treatment (failure)
infection pairs; pairs with identical genotypes are classiﬁed
as recrudescences, and those with different genotypes as
re-infections. Misclassiﬁcation may, however, occur when,
by chance, patients are re-infected with a strain having a
genotype identical to that of the pre-treatment infection.
The chance of this occurring in Bundi Bugyo was evaluated
as follows. First, the three-locus genotypes of 106 randomly
chosen samples were determined; the population fre-
quency of each three-locus genotype was then calculated
[¼ (number of samples with genotype X)/106]. This
frequency also represented the probability [known as
P(match)] that a patient could have been re-infected with a
strain of identical genotype. For any of the three-locus
genotypes found in the study population, P(match) was
<0.03, namely within the accepted limit (0.05) stipulated by
this method: identical-genotype pairs could thus reliably be
classiﬁed as recrudescences, and vice versa.
Sample size
Sample sizes for the SP and AQ groups were determined
applying a Type I error risk of 0.05, a power of 0.80 and a
projected 10% loss to follow-up. Assuming 40% failure,
and with a desired precision of 10%, 100 children were to
be included in the SP group, while in the AQ group,
assuming 10% failure, and with 7.5% precision, an
intended sample size of 70 was set. Sample size in the
CQ + SP group was arbitrarily set at 90 based on
EANMAT standards (minimum, n ¼ 60, based on lot
quality assurance sampling; ideal, n ¼ 120, based on
classical sample size calculation) and the projected speed of
enrolment.
Data entry and analysis
Data were double-entered and analysed per-protocol on
epiinfo 6.04b (CDC, Atlanta, 1996). The proportion of
recrudescences found among PCR-analysed failures was
applied to failures after day 9 for which no PCR result was
available, and an extrapolated number of failures was
obtained. The overall number of failures in each treatment
group was thus calculated as ETF + LCF before or on
day 9 + all other LCF or LPF conﬁrmed or extrapolated as
true recrudescences from the PCR analysis. Anaemia was
deﬁned as haemoglobin <11 g/dl. Percent gametocyte
carriage was compared among study groups by a
chi-square test.
Results
Between January and November 2002, 5901 children
were screened, of whom 685 (11.6%) were positive for
P. falciparum. Of these, 268 met inclusion criteria: 100
received SP, 78 AQ and 90 CQ + SP. Baseline character-
istics (Table 1) were similar across treatment groups, with
the exception of gametocyte carriage (P < 0.01). After
inclusion, 3.7% (10/268) of children were lost to
follow-up, and 7.1% (19/268) were withdrawn due to
incorrect inclusion (5), intake of non-study antimalarials
(4), vomiting dose twice (3), incorrect dosage (3), acute
respiratory infection (2) and re-infection with a non-
falciparum species (2).
Clinical failure proportions at day 14 (ETF + LCF days
4–14), without PCR adjustment, were highest in SP group
(23.4%), compared to 8.8% and 6.0% in the AQ and
CQ + SP groups, respectively (Table 2). After PCR adjust-
ment,overall(ETF + LCF + LPF)failureproportionsatday
28increasedconsiderablyinallgroups,butremainedhighest
among SP patients (37.0%), whereas failure in the AQ and
CQ + SP groups was similar (20.6% and 22.8%, respect-
ively), and signiﬁcantly lower than for SP (P < 0.05 for both
SP vs. AQ and SP vs. CQ + SP comparisons). Early failures
were also more frequent in the SP group (P < 0.05 for both
comparisons). Parasite clearance on day 3 was only 56.3%
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AQ group and 74.7% (62/83) in the CQ + SP group
(P < 0.02 for the same comparisons).
Baseline gametocyte carriage was 26.0% (26/100) in the
SP group, reached 44.0% (43/80) on day 14 and remained
at 25.4% (15/59) on day 28 among patients who were still
being followed-up. Baseline carriage was lower and com-
parable in the AQ (5/78 or 6.4%) and CQ + SP (6/90 or
6.7%) groups. By day 14, however, it was only 1.5% (1/
68) in the AQ group, compared to 25.9% (21/81) in the
CQ + SP group (P < 0.05). Gametocytaemia in both
groups was low on day 28 [0.0% (0/44) and 5.2% (3/58)].
Of 62 children anaemic on day 0 and re-assessed on day
28, 52 (83.9%) presented a haemoglobin level higher than
baseline. Between day 4 and day 28, 70 children with
reappearingparasitesbutnofeverwerefollowed-upwithout
rescue treatment; of these, 46 (65.7%) developed fever
(LCF), 20 (28.6%) remained afebrile but parasitaemic up to
day28(LPF)andonlyfour(5.7%)clearedparasites(ACPR).
This pattern was similar in all treatment groups.
Discussion
This in vivo study provides fresh data on antimalarial
efﬁcacy in a border area of Uganda where information on
resistance was scarce. Speciﬁcally, it offers new informa-
tion on the performance of CQ + SP (Uganda’s ﬁrst-line
antimalarial regimen) based on a PCR-adjusted 28-day
follow-up, rather than the less ideal 14-day method.
The main limitation of this study was its non-random-
ized design, making a comparison of study regimens
difﬁcult: enrolment in the treatment groups occurred in
different transmission seasons, with potentially different
ecological balances of resistant strains. Different trans-
mission intensity during enrolment of each study group
should not have created a large bias in outcome, as PCR
would have detected re-infections. Failure to randomize,
nevertheless, means that inter-group comparisons should
be interpreted with caution (this is particularly the case for
gametocyte carriage, which was clearly higher at baseline
in the SP group). Also, exclusion of children with a
Table 1 Baseline (day 0) characteristics of
included patients (in vivo antimalarial
efﬁcacy study, Bundi Bugyo, Uganda, 2002)
Characteristic SP (n ¼ 100) AQ (n ¼ 78) CQ + SP (n ¼ 90)
Age (months),
mean (standard deviation)
25.3 (12.5) 19.7 (10.3) 24.2 (13.8)




142.1 (11.5) 141.9 (11.9) 145.1 (13.3)
Axillary temperature ( C),
median (range)













26.0 (17.7–35.7) 6.4 (2.1–14.3) 6.7 (2.5–13.9)
Haemoglobin (g/dl),
median (range)
11.7 (5.3–15.3) 11.7 (6.0–15.3) 10.7 (6.7–14.0)
Table 2 Clinical failure proportions at day 14 (ETF + LCF, no PCR adjustment) and overall failure proportions at day 28
(ETF + LCF + LPF, after PCR adjustment) (in vivo antimalarial efﬁcacy study, Bundi Bugyo, Uganda, 2002)
Day
Outcome Clinical failure, day 14 Overall failure, day 28
ETF LCF LCF LPF
n % 95% CI n % 95% CI 1–3 4–14 15–28 28
SP 14 8 18 22 22/94 23.4 15.3–33.3 34/92* 37.0 27.1–47.7
AQ 0 6 18 5 6/68 8.8 3.3–18.2 14/68 20.6 11.7–32.7
CQ + SP 3 2 18 12 5/84 6.0 2.0–13.3 18/79 22.8 14.1–33.6
* SP: 17 failures before or on day 9 + 15 PCR-conﬁrmed (8 LCF, 7 LPF) + 5 extrapolated (LCF or LPF).
 AQ: 0 failures before or on day 9 + 11 PCR-conﬁrmed (10 LCF, 1 LPF) + 3 extrapolated (LCF or LPF).
 CQ + SP: 3 failures before or on day 9 + 10 PCR-conﬁrmed (9 LCF, 1 LPF) + 5 extrapolated (LCF or LPF).
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resulted in an underestimation of treatment failure, as
patients highly suspect of harbouring a resistant strain were
systematically left out. Malabsorption could have played a
role in some failures: we did not attempt to measure drug
concentrations in plasma, as this entails a lengthy proce-
dure rarely performed in antimalarial efﬁcacy monitoring.
Enrolment in the study lasted 9 months: the proportion of
children with conﬁrmed malaria was lower than expected,
suggesting that the disease’s burden may have been
overestimated in Bundi Bugyo.
Our results show that SP resistance has reached alarming
levels in Bundi Bugyo, up nearly ﬁvefold from 1997
considering day 14 clinical failure only. The proportion of
early failures is particularly concerning. Addition of CQ to
SP did seem to improve therapeutic response (notably in
the early stage), mirroring ﬁndings from Kampala (Gasa-
sira et al. 2003). However, the combination’s overall
efﬁcacy was disappointing (23% failure), and already in
the ‘action’ period requiring activities to identify a
replacement therapy (WHO 2000b). Gametocyte carriage
was also high after both SP and CQ + SP treatment, with
important implications for community transmission of
P. falciparum, and especially resistant strains (Sokhna et al.
2001; Bousema et al. 2003). In Bundi Bugyo, SP does not
seem like a viable partner drug for a combination regimen.
Elsewhere in Uganda, as SP resistance builds, similar trends
may be expected (Talisuna et al. 2002).
In this study, moderate resistance to AQ (21%) was also
noted, though no ETF and rapid gametocyte clearance
were observed. In Bundi Bugyo, a combination of artesu-
nate (AS) and AQ could prove efﬁcacious (Adjuik et al.
2002), and, if used correctly, slow or reverse the develop-
ment of resistance, as shown elsewhere (Nosten & Brasseur
2002). Artemether plus lumefantrine (Coartem
 ) could be
a second option. Both of these artemisinin-based combi-
nations, however, remain considerably more expensive
than currently used regimens.
Methodologically, our in vivo study conﬁrms the
importance of extending follow-up to at least 28 days, as
evidenced elsewhere in Uganda (Dorsey et al. 2002). In this
setting, a follow-up of only 14 days would have seriously
underestimated failure proportions. Our ﬁndings also
demonstrate the relevance of parasitological (LPF) criteria
of failure, recently added to the WHO classiﬁcation: of
children with asymptomatic parasitaemia during follow-up,
two-thirds became symptomatic, and only 6% spon-
taneously eliminated their parasites, conﬁrming results
from Tanzania (Mutabingwa et al. 2001). Early and late
recrudescences may be intrinsically different because of
strain virulence or host immunity (White 2002). Never-
theless, our study suggests that, among children in a setting
such as Bundi Bugyo, LPF represents merely the pre-clinical
stage of the recrudescence process, and is thus a valid
criterion of therapeutic failure.
In summary, this study from western Uganda highlights
the need to prepare a change in the current ﬁrst-line
antimalarial protocol. We believe our ﬁndings discourage
the future long-term deployment of SP containing combi-
nations in this region, as their useful therapeutic lifespan is
expected to be short. In Bundi Bugyo, an AS + AQ
combination should be prioritized. Policy decisions should
be based on in vivo studies with a follow-up of at least
28 days, PCR genotyping to detect reinfections, and both
clinical and parasitological criteria of failure.
Acknowledgements
We are grateful to all children and their families for their
kind participation, to local authorities for their support and
to the Ministry of Health of Uganda for the successful
cooperation. Salim Ahmed, Eugene Airinatwe, Elizabeth
Amanya, David Bagonza, Moses Balisingura, Happy
Bwambale, Emmanuel Ejoku, Michael Idha, Shalala Jannet
and Ismail Mulungula comprised the study team. Many
thanks to Gaspard Guma (Ministry of Health) for his
appreciated site visits, to Carole Fogg (Epicentre) and James
Kiguli (Mbarara University of Science and Technology) for
organising quality control of slides, and to Franc ¸ois Nosten
(Shoklo Malaria Research Unit) for facilitating PCR analy-
sis. Thanks also to Christine Genevier, Catherine Hamel,
Dominique van den Meerschaut and Benedicte Jardot (MSF
Uganda),toMarlonGarcia,Marie-MadeleineLeplomband
Pierre Salignon (MSF Paris) for supporting the study. This
research was ﬁnanced by Me ´decins Sans Frontie `res.
References
Adjuik M, Agnamey P, Babiker A et al. (2002) Amodiaquine–
artesunate versus amodiaquine for uncomplicated Plasmodium
falciparum malaria in African children: a randomised, multi-
centre trial. Lancet 359, 1365–1372.
Bojang KA, Schneider G, Forck S et al. (1998) A trial of Fansidar
plus chloroquine or Fansidar alone for the treatment of
uncomplicated malaria in Gambian children. Transactions of
the Royal Society of Tropical Medicine and Hygiene 92, 73–76.
Bousema JT, Gouagna LC, Meutstege AM et al. (2003) Treatment
failure of pyrimethamine–sulfadoxine and induction of Plas-
modium falciparum gametocytaemia in children in western
Kenya. Tropical Medicine and International Health 8, 427–430.
Brockman A, Paul REL, Anderson T et al. (1999) Application of
genetic markers to the identiﬁcation of recrudescent Plasmo-
dium falciparum infections on the north western border of
Thailand. American Journal of Tropical Medicine and Hygiene
60, 14–21.
Tropical Medicine and International Health volume 9 no 4 pp 445–450 april 2004
F. Checchi et al. Antimalarial efﬁcacy in Western Uganda: 28-day in vivo results
ª 2004 Blackwell Publishing Ltd 449Dorsey G, Njama D, Kamya MR et al. (2002) Sulfadoxine/
pyrimethamine alone or with amodiaquine or artesunate for
treatment of uncomplicated malaria: a longitudinal randomised
trial. Lancet 360, 2031–2038.
East African Network for Monitoring Antimalarial Treatment
(EANMAT) (1999) In vivo Antimalaria Drug Efﬁcacy Tests:
Field Workers’ Guide/Manual, 1st edn. EANMAT, Nairobi.
Gasasira AF, Dorsey G, Nzarubara B et al. (2003) Comparative
efﬁcacy of aminoquinoline–antifolate combinations for the
treatment of uncomplicated falciparum malaria in Kampala,
Uganda. American Journal of Tropical Medicine and Hygiene
68, 127–132.
Jelinek T, Proll S, Hess F et al. (1996) Geographic differences in
the sensitivity of a polymerase chain reaction for the detection of
Plasmodium falciparum infection. American Journal of Tropical
Medicine and Hygiene 55, 647–651.
Kamya MR, Dorsey G, Gasasira A et al. (2001) The comparative
efﬁcacy of chloroquine and sulfadoxine–pyrimethamine for the
treatment of uncomplicated falciparum malaria in Kampala,
Uganda. Transactions of the Royal Society of Tropical Medicine
and Hygiene 95, 50–55.
Kamya MR, Bakyaita NN, Talisuna AO, Were WM & Staedke SG
(2002) Increasing antimalarial drug resistance in Uganda and
revision of the national drug policy. Tropical Medicine and
International Health 7, 1031–1041.
Legros D, Johnson K, Houpikian P et al. (2002) Clinical efﬁcacy of
chloroquine or sulfadoxine–pyrimethamine in children under
ﬁve from south-western Uganda with uncomplicated falciparum
malaria. Transactions of the Royal Society of Tropical Medicine
and Hygiene 96, 199–201.
Ministry of Health of Uganda (2003) Statistical Abstract, Year
2002. Resource Center, Kampala.
Mutabingwa T, Nzila A, Mberu E et al. (2001) Chlorproguanil–
dapsone for treatment of drug-resistant falciparum malaria in
Tanzania. Lancet 358, 1218–1223.
Nosten F & Brasseur P (2002) Combination therapy for malaria:
the way forward? Drugs 62, 1315–1329.
Sokhna CS, Trape JF & Robert V (2001) Gametocytaemia in
Senegalese children with uncomplicated falciparum malaria
treated with chloroquine, amodiaquine, or sulfadoxine +
pyrimethamine. Parasite 8, 243–250.
Talisuna AO, Langi P, Bakyaita N et al. (2002) Intensity of
malaria transmission, antimalarial-drug use and resistance in
Uganda: what is the relationship between these three factors?
Transactions of the Royal Society of Tropical Medicine and
Hygiene 96, 310–317.
White NJ (2002) The assessment of antimalarial drug efﬁcacy.
Trends in Parasitology 18, 458–464.
WHO (1991) Basic Malaria Microscopy, Parts I and II. WHO,
Geneva.
WHO (2000a) Severe falciparum malaria. Transactions
of the Royal Society of Tropical Medicine and Hygiene 94,
1–90.
WHO (2000b) The Use of Antimalarial Drugs, Report of an
Informal Consultation, 13–17 November 2000. WHO, Geneva,
(WHO/CDS/RBM/2001.33).
WHO (2002) Monitoring Antimalarial Drug Resistance, Report of
a WHO Consultation, 3–5 December 2001. WHO, Geneva
(WHO/CDS/RBM/2002.39).
Authors
Francesco Checchi (corresponding author), Gerardo Priotto and Jean-Paul Guthmann, Epicentre, 8 rue Saint-Sabin, 75011, Paris,
France. Tel.: +33 1 4021 2904; Fax: +33 1 4021 2803; E-mail: fchecchi@epicentre.msf.org, gpriotto@epicentre.msf.org,
jguthmann@epicentre.msf.org
Patrice Piola, Epicentre, Kampala, Uganda. Tel.: +256 77 72 1746; E-mail: epicentre@imul.com
Cara Kosack, Elisa Ardizzoni, Derryck Klarkowski and Suna Balkan,M e ´decins Sans Frontie `res, 8 rue Saint-Sabin, Paris, France.
E-mail: cakos74@yahoo.com, elisardizzoni@yahoo.it, derryck.klarkowski@amsterdam.msf.org, sbalkan@paris.msf.org
Nathan Bakyaita, Malaria Control Programme, Ministry of Health, Kampala, Uganda. Tel.: +256 41 340 884.
E-mail: natsbach@hotmail.com
Alan Brockman, Shoklo Malaria Research Unit, Mae Sot, Thailand. E-mail: al_brockman@yahoo.co.uk
Tropical Medicine and International Health volume 9 no 4 pp 445–450 april 2004
F. Checchi et al. Antimalarial efﬁcacy in Western Uganda: 28-day in vivo results
450 ª 2004 Blackwell Publishing Ltd